JP7154238B2 - Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法 - Google Patents

Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法 Download PDF

Info

Publication number
JP7154238B2
JP7154238B2 JP2019571194A JP2019571194A JP7154238B2 JP 7154238 B2 JP7154238 B2 JP 7154238B2 JP 2019571194 A JP2019571194 A JP 2019571194A JP 2019571194 A JP2019571194 A JP 2019571194A JP 7154238 B2 JP7154238 B2 JP 7154238B2
Authority
JP
Japan
Prior art keywords
mast4
composition
extracellular matrix
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019571194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513849A5 (OSRAM
JP2020513849A (ja
Inventor
ジン キム，ソン
ソン ジョン，ハン
高橋，智
Original Assignee
キム，セロン
キム，イェン ウォン ジュン
キム，イプセ
ジン キム，ソン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キム，セロン, キム，イェン ウォン ジュン, キム，イプセ, ジン キム，ソン filed Critical キム，セロン
Priority claimed from PCT/KR2018/002763 external-priority patent/WO2018164507A2/ko
Publication of JP2020513849A publication Critical patent/JP2020513849A/ja
Publication of JP2020513849A5 publication Critical patent/JP2020513849A5/ja
Priority to JP2022159928A priority Critical patent/JP7498239B2/ja
Application granted granted Critical
Publication of JP7154238B2 publication Critical patent/JP7154238B2/ja
Priority to JP2024087859A priority patent/JP2024116197A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019571194A 2017-03-08 2018-03-08 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法 Active JP7154238B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022159928A JP7498239B2 (ja) 2017-03-08 2022-10-04 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法
JP2024087859A JP2024116197A (ja) 2017-03-08 2024-05-30 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20170029607 2017-03-08
KR10-2017-0029607 2017-03-08
KR1020180027111A KR102588627B1 (ko) 2017-03-08 2018-03-07 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법
KR10-2018-0027111 2018-03-07
PCT/KR2018/002763 WO2018164507A2 (ko) 2017-03-08 2018-03-08 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022159928A Division JP7498239B2 (ja) 2017-03-08 2022-10-04 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法

Publications (3)

Publication Number Publication Date
JP2020513849A JP2020513849A (ja) 2020-05-21
JP2020513849A5 JP2020513849A5 (OSRAM) 2021-04-15
JP7154238B2 true JP7154238B2 (ja) 2022-10-17

Family

ID=63718648

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019571194A Active JP7154238B2 (ja) 2017-03-08 2018-03-08 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法
JP2022159928A Active JP7498239B2 (ja) 2017-03-08 2022-10-04 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法
JP2024087859A Pending JP2024116197A (ja) 2017-03-08 2024-05-30 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022159928A Active JP7498239B2 (ja) 2017-03-08 2022-10-04 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法
JP2024087859A Pending JP2024116197A (ja) 2017-03-08 2024-05-30 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法

Country Status (7)

Country Link
US (2) US11180573B2 (OSRAM)
EP (1) EP3594324A4 (OSRAM)
JP (3) JP7154238B2 (OSRAM)
KR (1) KR102588627B1 (OSRAM)
CN (1) CN110612348B (OSRAM)
AU (2) AU2018231559A1 (OSRAM)
CA (1) CA3055729A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230050202A1 (en) * 2020-01-16 2023-02-16 The Johns Hopkins University Engineered fibroblasts as cell therapy to treat cancer via tumor stroma stabilization
US20240299579A1 (en) * 2020-07-23 2024-09-12 Orthobio Therapeutics, Inc. Gene editing to improve joint function
KR20240147995A (ko) * 2022-02-04 2024-10-10 김성진 뼈 및 연골을 제조하는 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503643A (ja) 2009-09-03 2013-02-04 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
JP2016531147A (ja) 2013-09-09 2016-10-06 フィジーン、エルエルシーＦｉｇｅｎｅ， Ｌｌｃ コンドロサイトまたは軟骨型細胞の再生のための遺伝子治療
WO2017123951A1 (en) 2016-01-14 2017-07-20 Spinacyte, Llc Cellular blend for the regeneration of chondrocytes or cartilage type cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055298A (en) * 1987-12-01 1991-10-08 Chemisches Laboratorium Dr. Kurt Richter Gmbh Cosmetic composition comprising an extracellular connective tissue matrix
US6528052B1 (en) * 2000-09-29 2003-03-04 The Board Of Trustees Of The Leland Stanford Junior University Method for in vivo ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling
WO2005121316A1 (en) * 2004-06-11 2005-12-22 Bernard O'brien Institute Of Microsurgery Tissue material and muscle derived matrix
KR100614903B1 (ko) * 2004-08-06 2006-08-25 테고사이언스 (주) 케라티노사이트 및/또는 섬유아세포를 함유하는 화장용조성물
EP1894581A1 (en) * 2006-08-31 2008-03-05 CellCoTec B.V. Repair of cartilage tissue using a matrix gel containing chondrocytes
JP2011526585A (ja) * 2008-03-31 2011-10-13 スカルセル テラピュティク 皮膚の老化の美容的処置法
WO2012083363A1 (en) * 2010-12-22 2012-06-28 Murdoch Childrens Research Institute A method of treatment
WO2013034989A2 (en) * 2011-09-07 2013-03-14 3-D Matrix, Ltd. Microrna-based methods and assays for osteosarcoma
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
KR102039311B1 (ko) 2012-09-07 2019-11-04 주식회사 마크로젠 Ａｘｌ을 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물
JP2016538341A (ja) * 2013-11-14 2016-12-08 デルマルシェ・ラブス・エルエルシー 線維芽細胞混合物ならびにその作製方法および使用方法
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503643A (ja) 2009-09-03 2013-02-04 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
JP2016531147A (ja) 2013-09-09 2016-10-06 フィジーン、エルエルシーＦｉｇｅｎｅ， Ｌｌｃ コンドロサイトまたは軟骨型細胞の再生のための遺伝子治療
WO2017123951A1 (en) 2016-01-14 2017-07-20 Spinacyte, Llc Cellular blend for the regeneration of chondrocytes or cartilage type cells

Also Published As

Publication number Publication date
CN110612348B (zh) 2024-02-09
CA3055729A1 (en) 2018-09-13
KR20180103015A (ko) 2018-09-18
JP2024116197A (ja) 2024-08-27
US20200239596A1 (en) 2020-07-30
JP7498239B2 (ja) 2024-06-11
CN110612348A (zh) 2019-12-24
KR102588627B1 (ko) 2023-10-16
AU2023222944B2 (en) 2026-03-05
US11180573B2 (en) 2021-11-23
EP3594324A4 (en) 2021-01-20
EP3594324A2 (en) 2020-01-15
JP2020513849A (ja) 2020-05-21
AU2018231559A1 (en) 2019-10-31
AU2023222944A1 (en) 2023-11-23
US20220220221A1 (en) 2022-07-14
JP2022188178A (ja) 2022-12-20

Similar Documents

Publication Publication Date Title
JP7556092B2 (ja) 遺伝子編集のための組成物および方法
JP7522656B2 (ja) 常染色体優性網膜色素変性の処置のための材料および方法
JP7498239B2 (ja) Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法
JP7277052B2 (ja) プロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）関連障害の処置のための組成物および方法
JP6932698B2 (ja) アルファ１アンチトリプシン欠乏症の治療のための材料および方法
JP7402163B2 (ja) ２ａ型アッシャー症候群の処置のための材料および方法
JP7544785B2 (ja) 疼痛関連障害を処置するための物質及び方法
JP2019520079A (ja) 疼痛関連障害を処置するための物質及び方法
JP2019534695A (ja) Ｒｎａ誘導型核酸修飾酵素及びその使用方法
CN109844123A (zh) 经人工操纵的血管生成调控系统
JP2022545462A (ja) Ｃｒｉｓｐｒ／ｃａｓ９ベースの転写活性化因子による骨格筋芽細胞前駆細胞系譜特定
KR101642202B1 (ko) Klf10 발현 억제제를 포함하는 연골세포 분화 촉진 또는 연골질환 치료용 조성물, 및 이를 이용한 연골분화 촉진 방법
WO2018164507A2 (ko) Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법
KR20250016667A (ko) Psme4 억제제를 포함하는 중간엽 줄기세포의 조골세포 분화 촉진용 조성물
CN119968464A (zh) 具有组合基因扰动的免疫细胞
Alnafisah Involvement of Drebrin in Microglial Activation and Inflammation
CN119768506A (zh) 制造骨骼和软骨的方法
WO2020024773A1 (zh) Yap与foxd1在制备治疗和/或预防动物骨关节炎产品中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221004

R150 Certificate of patent or registration of utility model

Ref document number: 7154238

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250